MM-111: Phase I data

Data from 29 evaluable patients in an open-label, dose-escalation, U.S. Phase I trial showed that once-weekly MM-111 in combination with chemotherapy led to a clinical benefit rate (CBR) of 52%. Specifically, MM-111

Read the full 320 word article

User Sign In